



PRISMA harms checklist

Section/Topic	#	Checklist Item	PRISMA harms (minimum)	Reported on Page #
TITLE				
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Specifically mention “harms” or other related terms, or the harm of interest in the review.	Title 1# (PRISMA harms not done)
ABSTRACT				
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.		Abstract 1#
INTRODUCTION				
Rationale	3	Describe the rationale for the review in the context of what is already known.		Introduction 1-2#
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).		Introduction 2#
METHODS				
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.		Methods 2-3#
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.		Selection criteria and Data extraction 2-3#
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.		Search strategy 2#
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.		Appendix: PubMed



PRISMA harms checklist

				search terms 2#
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).		Selection criteria 3#
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.		Data extraction 2#
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.		Selection criteria and Data extraction 3#
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.		Assessment for Risk 3#
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).		Selection criteria and Data extraction 2-3#
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Specify how zero events were handled, if relevant.	Statistical methods 3# (PRISMA harms done)

Page 1 of 2

Section/Topic	#	Checklist Item		Reported on Page #
---------------	---	----------------	--	--------------------



PRISMA harms checklist

Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).		Publication bias 3#
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.		subgroup analyses 3#
RESULTS				
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.		Results 3-4#
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Define each harm addressed, how it was ascertained (eg, patient report, active search), and over what time period.	Results 3-4# (PRISMA harms done)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).		Subgroups analysis 4#
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.		Relative risk for all AEs 4-5#
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	Describe any assessment of possible causality.	Results 4-5#(PRISMA harms done)
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).		Publication bias 5#
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).		subgroup analyses 4-5#
DISCUSSION				
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).		Discussion 5#
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research,		Discussion



PRISMA harms checklist

		reporting bias).		6#
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.		Discussion 6#
FUNDING				
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.		Funding 6#